This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Gregory Ligozio: Innovator in Psoriatic Arthritis Treatment
Introduction
Gregory Ligozio is a notable inventor based in Basking Ridge, NJ (US). He has made significant contributions to the field of medicine, particularly in the treatment of psoriatic arthritis. His innovative work has led to the development of methods that aim to inhibit the progression of structural damage in patients suffering from this condition.
Latest Patents
Ligozio holds 1 patent for his invention titled "Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients." This patent encompasses various methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits that utilize Interleukin-17 (IL-17) antagonists, such as IL-17 antibodies and their antigen-binding fragments, including secukinumab.
Career Highlights
Gregory Ligozio is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative treatments that address unmet medical needs in the field of rheumatology.
Collaborations
Ligozio has collaborated with esteemed colleagues, including Shephard Mpofu and Hanno Richards, to advance research and development in his area of expertise.
Conclusion
Gregory Ligozio's contributions to the treatment of psoriatic arthritis through his innovative patent demonstrate his commitment to improving patient outcomes. His work continues to influence the medical community and offers hope for those affected by this challenging condition.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile